Navidea Biopharma (NAVB) Reports In-Line Q4 EPS

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.1 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• BlackRock’s Rosenberg says inflation data key after jobs beat